Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.

Adicet Bio Inc.

The latest update is out from Adicet Bio ( ($ACET) ). On June 17, 2026, Adicet Bio, Inc. held its 2026 Annual Meeting of Stockholders, where invest...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ACET	$8.10	0.00%	36.38K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ACET	$8.10	0%	36.38K
3
4
5
6

ACET

ACET

Get Adicet Bio Inc. Data in Excel

Get Adicet Bio Inc. Data in Excel